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Abstract
Background: Xenoestrogens such as alkylphenols and the structurally related plastic byproduct bisphenol A have
recently been shown to act potently via nongenomic signaling pathways and the membrane version of estrogen
receptor-a. Though the responses to these compounds are typically measured individually, they usually
contaminate organisms that already have endogenous estrogens present. Therefore, we used quantitative medium-
throughput screening assays to measure the effects of physiologic estrogens in combination with these
xenoestrogens.
Methods: We studied the effects of low concentrations of endogenous estrogens (estradiol, estriol, and estrone) at
10 pM (representing pre-development levels), and 1 nM (representing higher cycle-dependent and pregnancy
levels) in combinations with the same levels of xenoestrogens in GH3/B6/F10 pituitary cells. These levels of
xenoestrogens represent extremely low contamination levels. We monitored calcium entry into cells using Fura-2
fluorescence imaging of single cells. Prolactin release was measured by radio-immunoassay. Extracellular-regulated
kinase (1 and 2) phospho-activations and the levels of three estrogen receptors in the cell membrane (ERa,E R b,
and GPER) were measured using a quantitative plate immunoassay of fixed cells either permeabilized or
nonpermeabilized (respectively).
Results: All xenoestrogens caused responses at these concentrations, and had disruptive effects on the actions of
physiologic estrogens. Xenoestrogens reduced the % of cells that responded to estradiol via calcium channel
opening. They also inhibited the activation (phosphorylation) of extracellular-regulated kinases at some
concentrations. They either inhibited or enhanced rapid prolactin release, depending upon concentration. These
latter two dose-responses were nonmonotonic, a characteristic of nongenomic estrogenic responses.
Conclusions: Responses mediated by endogenous estrogens representing different life stages are vulnerable to
very low concentrations of these structurally related xenoestrogens. Because of their non-classical dose-responses,
they must be studied in detail to pinpoint effective concentrations and the directions of response changes.
Background
Xenoestrogens are small lipophillic molecules that
mimic physiological estrogens [1], and whose exposures
have been linked to a variety of disease states [2-11],
even when present at concentrations far below those
currently allowed by federal regulations. We previously
found that both physiologic estrogen metabolites and a
number of environmental estrogens have potent activ-
ities via the nongenomic pathway of estrogen signaling
[12-19], whereas they have been shown to be rather
weak via genomic signaling mechanisms [20-25]. There-
fore, inactivity in genomic assays does not necessarily
predict the same via nongenomic mechanisms. A variety
of xenoestrogens representing different chemical and
use classes has been examined for nongenomic signaling
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any medium, provided the original work is properly cited.pathway activities. Alkylphenols are of particular interest,
as they represent a structurally related set of compounds
that differ in the lengths of their carbon side-chain modi-
fications at position 4 on the phenol ring, or in the case
of bisphenol A (BPA) have another phenolic ring in place
of the side-chain (see Figure 1 for structures and human
blood levels [26-29]). The use of alkylphenols as indus-
trial surfactants results in contamination of many of our
waterways [30,31]. BPA can contaminate the environ-
ment in significant amounts by leaching from products
(plastic food and water containers, dental sealants, and
some cash register receipts), and as byproducts of manu-
facturing [32-34].
There are three candidate estrogen receptors (ERs) via
which estrogenic and xenoestrogenic responses can
operate. The classical ERs a and b have been described
in the membrane of these and other cells [35-43]. GPER
is a transmembrane ER in the GPCR family. It has been
shown to mediate a wide range of responses to estro-
gens in different cell types [44]. Because many of the
endpoints that it drives are different than those of the
classical ERs a and b (though often using overlapping
signaling pathways) [45], it may be a complementary
estrogen signaling system in ways that we do not yet
fully understand. Estrogens bind with different affinities
to these different ER types [46,47], which could provide
diverse physiological outcomes in unique circumstances
or stages of development.
We previously compared the signaling activities of
many physiological estrogens and xenoestrogens to
those of estradiol (E2) in pituitary and neuronal cells,
gaining some insight into how their chemical structure
may correlate with their estrogenic activity [1,15]. These
compounds signal predominantly via membrane recep-
tors for ERa (mERa) [15,18,19], with compensatory
actions sometimes occurring via mERb or GPER when
they are simultaneously present with mERa [42]. Other
studies have also demonstrated potent activities of some
of these xenoestrogens in pancreatic islet cells [10], neu-
ronal cells and tissues [48,49], cells of the immune sys-
tem [8,50], and a wide variety of other cell or tissue
experimental systems [51]. There are also many more
studies describing the activities of these compounds at
much higher concentrations, which may or may not act
via receptors, but have limited applicability to our con-
cern about prevalent environmental concentrations.
Lifelong exposure to E2 and potent synthetic estrogens
is also known to be an important consideration for the
development of cancers in reproductive tissues [52-55],
so there is a possibility that xenoestrogens could like-
wise contribute to these types of disease. Xenoestrogens
can cause proliferation of cells, as we demonstrated for
octylphenol (OP), nonylphenol (NP), and BPA in our
GH3/B6/F10 cell model ([15] and reports cited therein).
Few studies have examined the ability of low concen-
trations of xenoestrogens in combination with physiolo-
gic estrogens to alter their responses. In some cases the
combined presence of these estrogens can be inferred
b e c a u s et h es t u d i e sw e r ed o n ei ng o n a d a l l yi n t a c ta n i -
mals or in tissues isolated from such animals treated in
vivo [8,49,56-59]. Because of the non-monotonic con-
centration-responses typical of nongenomic estrogenic
responses [12,13,15,17,19,42,60,61], wide concentration
ranges and multiple combinations must be assessed
using quantitative, relatively high-throughput endpoints
to determine the real profile of xenoestrogen dose-based
activities. Here we extend our earlier assays of individual
estrogens and xenoestrogens shown to be active in non-
genomic responses, to assays of their combinatorial
effects. We have developed these assays in pituitary
cells, where the responses relate to a variety of cellular
responses and functions, including intracellular calcium
(Ca) levels; the phospho-activation of extracellular regu-
lated kinases (ERKs 1 and 2) as representatives of the
mitogen-activated protein kinase (MAPK) family often
involved in cellular remodeling, proliferation or death;
Xenoestrogens Serum 
Concentrations
4-Ethylphenol Not reported
4-Propylphenol Not reported
4- Octylphenol ND-5.57 nM
4-Nonylphenol ND-68.84 nM
Bisphenol A ND-17.52 nM
Figure 1 Chemical structures and reported serum levels of
xenoestrogens used in our study [26-29]. ND (non-detectable).
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Page 2 of 13and the release by the pituitary of a major peptide hor-
mone, prolactin (PRL).
E2 (in the pM to nM range) is the physiologic estro-
gen most often associated with female development and
specific reproductive function (see Figure 2). Relevant
concentrations range across more than two orders of
magnitude from early developmental levels up to those
that direct function during the reproductive years. How-
ever, other endogenous estrogens such as estrone (E1)
and estriol (E3) are more prevalent during other life
phases, and may have significant effects on tissue devel-
opment, function, and disease states. E1 is a significant
estrogenic hormone contributor in both reproductive
(~0.5-10 nM) and postmenopausal (150-200 pM)
women, and in men; E3 levels are much higher in preg-
nant (~10-100 nM) than in nonpregnant (<7 nM)
women [62]. Low E3 levels in pregnancy have been asso-
ciated with complications of eclampsia [63] and the inci-
dence of Down’s syndrome in offspring [64]. All three of
these endogenous estrogens are also produced by aro-
matases in a number of non-reproductive tissues, where
their effects may extend beyond reproductive functions
[65]. One example is that E3 has protective effects
against the development of arthritis in certain experi-
mental models [66], as had been known previously for
E2. Effects in brain, bone, the cardiovascular system, and
many other tissues may be affected differentially by
these three endogenous estrogenic compounds during
different life stages; therefore, loss or enhancement of
these effects due to interference by xenoestrogenic com-
pounds could affect human health in a large number of
tissues. Though it has recently been determined that E1
and E3 can act potently via nongenomic steroid signal-
ing mechanisms in several tissues, including pituitary
and neuronal cells [12,13,67,68], we do not know if
xenoestrogens can interfere with these activities when
they are present in combination, as is typical with expo-
sures to humans and animals living in a contaminated
environment.
The subcellular trafficking of signaling proteins is a
critical consideration for their function, because many
actions require close associations of cross-activating and
signal-transducing proteins. In this regard, steroid recep-
tors have been found to reside in the caveolar subcom-
partment of plasma membranes [69-71] in addition to
the nuclear compartment, and the entry and exit of pro-
teins from these compartments, and locations in
between, tells part of the story of their participation in
cellular regulation. We have recently found in other sys-
tems and with other estrogens that estrogenic actions
can also lead to trafficking of ERs in and out of the
plasma membrane [13,42]. Here we look at changes in
Figure 2 Levels of physiologic estrogens during different life stages in females compared to males. These data were graphed from
information summarized in a textbook [62], and span concentrations over 2 orders of magnitude. Levels over time and different stages are
shown by lines, and point values are shown as symbols, all labeled directly on the graph. Cycle phases are labeled on the timeline as EF (early
follicular), PO (preovulatory), MP (mid cycle-peak), L (luteal), PM (post menopausal), and P (pregnant, peak levels). The levels of the estrogens
estrone, estradiol, and estriol (E1,E 2, and E3, respectively) are shown for females (♀) and males (♂)
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Page 3 of 13the membrane location of ERs to better understand how
xenoestrogens may alter the nongenomic actions of phy-
siologic estrogens by re-locating their receptors to sites
where nongenomic signaling partners may be less
available.
Our tests of physiologic estrogens examine concentra-
tions that might be experienced due to normal mamma-
lian levels of the endogenous hormones at different life
stages. A 10 pM concentration would approximate early
developmental (infant) levels (see Figure 2), and a 100×
higher 1 nM concentration of these hormones would
approximate concentrations experienced during
menstrual cycling or early pregnancy. We then super-
imposed upon those endogenous estrogen levels a fre-
quently encountered very low contaminant concentration
range of alkylphenols and BPA (10 pM and 1 nM) to see
how normal signaling and functional endpoints would be
affected.
Methods
Materials and treatments
We purchased phenol red-free Dulbecco modified Eagle
medium (DMEM, high glucose) from Mediatech (Hern-
don, VA); horse serum from Gibco BRL (Grand Island,
NY); defined supplemented calf sera and fetal bovine
sera from Hyclone (Logan, UT). Paraformaldehyde and
picric acid were purchased from Fisher Scientific (Pitts-
burgh, PA). BPA (bisphenol A), EP (4-n-ethylphenol),
PP (4-n-propylphenol), OP (4-n-octylphenol), and NP
(4-n-nonylphenol), and other materials were purchased
from Sigma (St. Louis, MO). The antibody (Ab) for
phosphorylated (pERK) was purchased from Cell Signal-
ing Technology (Danvers, MA), for clathrin (mouse
anti-clathrin monoclonal) from ICN Biomedicals (Aur-
ora, OH), for ERa (MC-20) from Santa Cruz Biotech-
nology (Santa Cruz, CA), for ERß (Clone9.88) from
Sigma, and for GPER (NLS4271) from Novus (Littleton,
CO). Vectastain ABC kits and biotin-conjugated second-
ary Abs were purchased from Vector Labs (Burlingame,
CA). GH3/B6/F10 cells were routinely propagated in
DMEM containing 12.5% horse serum, 2.5% defined
supplemented calf serum, and 1.5% fetal calf serum.
Cells were used between passages 10 and 20 and placed
in defined or charcoal-stripped serum-containing media
before assays for estrogenic activity.
Cytosolic free calcium ([Ca
2+]i) fluorescent imaging
Cells were plated on poly-D-Lysine-treated 35/22 mm
glass bottom dishes (Willco Wells, Amsterdam, Nether-
lands) at a density of 100,000 cells/mm
3.A f t e r4 8 - 7 2h
of culture, the cells were loaded with the calcium-sensi-
tive fluorescent dye Fura-2AM (Molecular Probes,
Eugene, OR) at 2.5 μM (1 h, RT), washed in a physiolo-
gic solution (150 mM NaCl, 5.5 mM KCl, 1 mM MgCl2,
4m MC a C l 2, 7 mM glucose, 10 mM HEPES, pH 7.4),
and incubated at RT for 1-4 h before live Ca imaging.
The imaging setup included a Nikon 200E microscope
with 40× SuperFluo lens and computer-controlled illu-
mination system (Sutter Instruments, Novato, CA)
equipped with a digital monochrome-cooled charge-
coupled device Roper Coolsnap HQ camera (Roper
Scientific, Tucson, AZ). Fluorescent emissions at 510
nm from regions corresponding to a single cell were
acquired online with the MetaFluor software (Universal
Imaging, Downington, PA). The signals were obtained
in dual 340 and 380 nm excitation mode and the aver-
age intensity of fluorescence in each region was used to
estimate 340:380 ratios (R), reflecting [Ca
2+]i. Meta-
Morph (Universal Imaging, Downington, PA) and Sig-
maPlot (Systat Software, San Jose, CA) scientific
software were used for conversion and analysis of the
acquired data. For quantitative measurement of changes
in live cells for [Ca
2+]i and oscillation frequency, the
AutoFit function of PeakFit software (Systat Software,
San Jose, CA) was used, with manual adjustments. The
peak threshold was chosen empirically as ΔR≥0.05. Indi-
vidual cells were considered responsive to estrogen
treatment when they demonstrated increases in [Ca
2+]i
oscillation frequency of at least 0.25 calcium spikes per
min (estimated during 10 min time interval) compared
to the basal level, and delayed by no more than 10 min
from the addition of any estrogen into the bath. Subse-
quent comparative analysis of cell responses was per-
formed on responsive cells only for changes in
intracellular Ca levels (ΔCa/ΔCa0; Figure 3D-F) and
changes in (ΔCa) oscillation frequency (Figure 3G-I).
Quantitative ERK phosphorylation and mER assays
We developed this assay to assess levels of activated
E R K s1a n d2i nf i x e dG H 3/B6/F10 cells [72]. Cells were
plated at 10,000 cells/well in poly-D-lysine-coated 96-
well plates, and growth media were replaced the next day
with DMEM containing 1% charcoal-stripped (4×) serum
for 48 hr. Cells were then washed and treated with differ-
ent estrogenic compounds in medium for 5 min, fixed
with 2% paraformaldehyde/0.2% picric acid at 4°C for 48
hr, then permeabilized with PBS/2% BSA/0.1% Triton
X-100 for 1 hr at RT. Cells were washed 3× with PBS and
treated with primary Ab against pERKs (p-Thr202/
Tyr204; 1:400 in PBS/1% BSA). After overnight incuba-
tion at 4°C, the cells were processed for signal develop-
ment with the Vectastain ABC kit (Vector Labs,
Burlingame, CA) as recommended by the company. Bio-
tin-conjugated secondary Ab was used at a 1:300 dilution.
Plates were incubated in the dark for 20 min at 37°C for
the generation of alkaline phosphatase product (para-
nitrophenol) and read at A405 in a model 1420 Wallace
microplate reader (Perkin Elmer, Waltham, MA).
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Page 4 of 13The number of cells in each well was estimated by the
crystal violet assay (see below) and used to normalize
signals.
The membrane localization of ERs is based on pre-
venting cell permeabilization by careful optimization of
fixation and handling techniques for a given cell type.
For measurements of mERs, the detergent permeabiliza-
tion step (above) was left out and the status of the cells’
permeabilization was measured by probing with Ab to
clathrin (residing just under the plasma membrane); a
low clathrin signal indicates intact cells [73]. Primary
Abs were used at 1:1000 for ERa Ab, 1:2000 for ERb
Ab, 1:1000 for GPER Ab, and 1:400 for clathrin Ab.
Prolactin assay
Cells (0.5-0.7 × 10
6) were plated in poly-D-lysine-coated
well of six-well plates. After serum deprivation in 1%
charcoal-stripped (4×) serum for 48 h, this medium was
removed and DMEM/0.1% BSA with hormone or the
appropriate vehicle control (ethanol) was added. The
Figure 3 Changes in calcium responses elicited by physiologic estrogens (PE) and xenoestrogens (XE), alone and in combination. The
level of Ca [compared to the pretreatment baseline (B) measurement for each assessed cell] was measured by Fura-2 imaging in cells treated
with 10 pM E2,E 1,o rE 3 or different 10 pM alkylphenols (EP, PP, OP, NP, or BPA), or physiologic estrogen and xenoestrogen combinations. (A-C)
% of cells responding to estrogens; (D-F) changes in accumulated intracellular calcium levels; (G-I) changes of calcium oscillation frequency. Note
- some baseline measurements (D-F) were too low to show up as bars on the graphs. * = p < 0.05 compared to control cells. # = p < 0.05
compared to E2,E 1,o rE 3 alone.
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Page 5 of 13cells were incubated for 2 min and centrifuged at 4°C
(350 × g, 5 min), and the supernatant was collected and
stored at -20°C. The PRL concentrations were deter-
mined using components of the rat PRL RIA kit from
the National Institute of Diabetes and Digestive and
Kidney Disease and the National Hormone and Pituitary
Program (Baltimore, MD). Briefly, RIA buffer (80% PBS,
20% DMEM, 2% normal rabbit serum), 100 μLc o l d
standard (rat PRL-RP-3) or unknown sample, rPRL-s-9
antiserum (final dilution of 1:437,500 in RIA buffer),
and [
125I]-rat-PRL (PerkinElmer, Wellesley, MA; 15,000
counts diluted in RIA buffer) were combined and incu-
bated overnight at 4°C. Anti-rabbit IgG (Sigma) was
added to a final dilution of 1:9, and the samples were
incubated at RT for 2 hr. Then 1 mL of polyethylene
glycol solution (1.2 M polyethylene glycol, 50 mM Tris,
pH 8.6) was added and samples were incubated at RT
for 15 min. After centrifugation at 4,000 × g for 10 min
at 4°C, the supernatant was decanted and the pellet was
counted in a Wizard 1470 Gamma Counter (PerkinEl-
mer, Boston, MA). The PRL concentration was then
normalized to the crystal violet (CV) values (estimates
of the number of cells in each well). These measure-
ments (n = 18) were done in 3 different experiments on
different days using different passages of cells.
Crystal violet assay
After being processed for the ERK, mER, and PRL
assays, cells were washed 3× with PBS to remove media
or para-nitrophenol and stained with 0.1% crystal violet
solution for 30 min, then destained in deionized water.
The dye was then released with 10% acetic acid, and the
A590 signal of the extract was read in a model 1420
Wallace microplate reader [74]. The crystal violet assay
has been shown previously to correlate well with other
cell counting methods [75] and is used for its conveni-
ence of combining with our other assays in this study.
Statistics
Data from [Ca
2+]i, pERK, mER, and PRL studies were
analyzed by one-way analysis of variance (ANOVA), fol-
l o w e db ym u l t i p l ec o m p a r i s o n sv s .c o n t r o lg r o u p
(Holm-Sidak method). Experiments were repeated at
least 2-3 times using different passages of cells on differ-
ent days. The Sigma Stat 3 program (Systat Software,
Inc.) was used for all statistical analysis, and significance
was accepted at p < 0.05.
Results
We previously observed that initial estrogenic triggering
of Ca influx into cells occurred at the same level for all
effective estrogen concentrations – an all-or-none
response [15,17]. (This is different from the other gradu-
ated responses seen when escalating estrogen
concentrations are presented to the same cells [19]).
Therefore we chose only one active low concentration
for all estrogenic compounds (10 pM) to represent a
very low and common contamination level. We rea-
soned that such a low but effective concentration could
best make the point regarding concern about prevalent
environmental contamination levels.
We measured the portion of cells that respond with
increases in Ca spiking (%, Figure 3A-C), the accumu-
lated Ca levels in responding cells (ΔCa/ΔCa0,F i g u r e
3D-F), and the Ca oscillation frequency (ΔCa oscillation,
Figure 3G-I). All estrogens, both physiologic and non-
physiologic, caused substantial responses in all three
types of Ca response measurements, as we have
observed previously [15]. Only the percentage of cells
responding to E2 was altered by combinations of physio-
logic estrogens with xenoestrogens. Attenuation was
caused by combinations with 10 pM EP, PP, or NP, but
not OP or BPA. Whether higher concentrations can
affect this and other parameters of Ca signaling studied
here will require further study.
Using higher through-put assays (in multi-well plates
for the ERK and PRL studies), we tested multiple estro-
gen concentrations. Figures 4 and 5 show how combina-
tions of two different endogenous estrogen
concentrations with two different concentrations of each
x e n o e s t r o g e n( 1 0p Ma n d1n Mf o ra l le s t r o g e n s )c a n
affect ERK activation and PRL release. These low con-
centrations of xenoestrogens correspond to ~20 ppb for
the 1 nM concentration, and 200 ppt for the 10 pM
concentration. They were chosen to represent high and
low values of serum and urine levels reported in Ameri-
cans [34]. For comparison, physiologic estrogens are
present in these assays at ~27 ppb and 270 ppt
concentrations.
In the ERK activation assays (Figure 4) both concen-
trations of all physiologic estrogens evoked responses.
Only short-chain alkylphenols (EP and PP), and some-
times BPA activated ERK; (all showed increased activity,
but not all instances were statistically significant).
Xenoestrogens often blocked physiologic estrogen acti-
vation, especially when the higher concentrations of
both estrogens were present (J-L). Demonstrating the
non-monotonic behavior of xenoestrogen responses, low
concentrations were sometimes more effective (disrup-
tive of this response) than higher concentrations (com-
pare A-F with G-L). The ability of BPA to disrupt
depended upon whether it was balanced with an equal
concentration of its paired physiologic estrogen (com-
pare A-C and J-L, with D-I). In these concentration sce-
narios, xenoestrogens never significantly enhanced a
physiologic estrogen response, as we have sometimes
seen at other concentrations [76]. There are many
instances where though a concentration of a long-chain
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Page 6 of 13alkylphenol or BPA was not active by itself, it could
nevertheless inhibit the paired physiologic estrogen’s
response (seen in all panels except E, F, and H). In gen-
eral, our data indicate that both high and low endogen-
ous hormone levels are vulnerable to even extremely
low xenoestrogen exposures, so both developing and
adult females, and males, could be affected by these
xenoestrogens.
In the PRL assays (Figure 5), both concentrations of
all physiologic estrogens evoked responses, except that
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OP, NP, or BPA), row labeled lo PE - lo XE; (D-F) 1 nM of the physiologic estrogens alone or in combinations with 10 pM of different
alkylphenols, row labeled hi PE - lo XE; (G-I) 10 pM of the physiologic estrogens alone or in combinations with 1 nM of different alkylphenols,
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Page 8 of 13E1 did not always cause a significant change (see B and
H). Alkylphenols always evoked PRL release at the lower
(pM) concentration (panels A-F), but only the long-
chain alkylphenols caused this response at the higher
(nM) concentration, indicating a non-monotonic beha-
vior of the short-chain alkylphenols. BPA did not cause
a response on its own at either of these concentrations,
though it has been observed to be active at other con-
centrations in this response [15,19].
Next we directed our attention to the ability of xenoes-
trogens to alter the release of PRL elicited by physiologic
estrogens. Both short-chain and long-chain alkylphenols
were able to block physiologic estrogen responses at
either high or low concentrations, intermittently across
this range of studies. Interestingly, when both xenoesto-
gens and physiologic estrogens were at the higher (nM)
concentration, the effect was more often an enhanced
release of PRL (panels J-L). Though not active by itself at
these concentrations, BPA could disrupt some physiolo-
gic estrogen actions across all paired compound concen-
trations, and was able to enhance release when its 1 nM
concentration was paired with a 1 nM E3 concentration
(panel L). Therefore, both of the tested endogenous hor-
mone levels were again vulnerable to alteration.
While for the ERK activations, xenoestrogens always
caused inhibition of the response, for the PRL release
response, 1/3 of the time the effect was instead
enhancement of the response (all at the adult endogen-
ous estrogen levels in combination with nM xenoestro-
gens). The chain length of the alkylphenols had some
influence, even if differently, on these combinatorial
responses with physiologic estrogens, though they were
not as pronounced as the previous structure-based
effects we saw when these xenoestrogens were adminis-
tered alone [1,15]. Overall, our stringent analysis by
ANOVA did not show significance of some effects that
would have been judged significant by a student’st - t e s t .
However, one can often see trends in the “non-signifi-
cant” data that still support these conclusions.
Finally, we studied the effects of all of these estrogens
on mER trafficking five minutes after hormone adminis-
tration (Figure 6), choosing this time because it is
unambiguously nongenomic, and because five-min
responses were universally present for both ERK and Ca
signaling pathways, and for the PRL secretion endpoint,
for all classes of estrogens [1,15]. We had previously
reported the lack of ERb in our cell line [37], as values
were not significantly different from controls (but did
have wide errors of measurement). Perhaps due to assay
improvements, cell line evolution, or change of Ab, we
now see measurable amounts of ERb in the membrane
of these GH3/B6/F10 cells; whole cell ERb had been
reported by others in the parent GH3 cell line previously
[77]. We detect a 57 kD band for ERbon an immunoblot
at the same migration distance as ERb isolated from
LNCAP human prostate cancer cells (data not shown).
Some xenoestrogen effects were seen at the 10 pM con-
centrations for most compounds; OP, NP and BPA all
decreased mERa, and PP decreased mERb. However,
these effects were more prominent at the higher (1 nM)
concentrations for all compounds. EP, PP, and BPA all
decreased mERa in the membrane; all alkylphenols and
BPA decreased mERb in the membrane. It is interesting
that physiologic estrogens also had some effects on
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Figure 6 Movement of mERs in or out of the membrane in response to different physiologic (E2,E 1,o rE 3 ) or environmental (EP, PP,
OP, NP, or BPA) estrogens. Levels were assessed by a quantitative plate assay measuring immunoreactive protein levels in the plasma
membrane for ERa,E R b, and GPER, after treatment with (A) 10 pM of estrogenic compounds or (B) 1 nM of estrogenic compounds for 5 min.
*p < 0.05 compared to vehicle (V) control cells. #:p < 0.05 compared to E2,E 1,o rE 3 alone.
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Page 9 of 13these mERs. E1, ࿠increased levels of mERb at the lower
concentration and E3 decreased levels of mERa at the
higher concentration. None of these estrogens signifi-
cantly changed GPER levels.
To validate that our measured receptor antigens were
in the membrane, and not the cell interior, we moni-
tored our fixation conditions for absence from acciden-
tal plasma membrane disruption. To do this, we
examined clathrin Ab recognition [73], expecting very
low levels of this intracellular antigen in unpermeabi-
l i z e dc e l l s .H e r ew es a wap N P / C Vv a l u eo f0 . 0 3 5±
0.002 for clathrin in unpermeabilized cells compared to
0.16 ± 0.004 for permeabilized cells, a 4.6-fold higher
value in permeabilized cells, as expected.
Discussion
It is clear from our studies that combining xenoestro-
gens with different physiologic estrogens (E1,E 2, and E3)
alters responses driven by life-stage-specific levels of the
endogenous estrogens. In some cases this caused inhibi-
tion of the physiologic response, while in others it
caused enhancement. When xenoestrogens disrupt
(either inhibit or enhance) estrogenic signaling, then
development, menstrual cycling, pregnancy, or post-
menopausal maintenance of estrogenic responses could
all be altered. Life stage-inappropriate responses could
terminate a pregnancy, cause infertility, cause birth
defects, or alter pituitary-dependent regulation. Exacer-
bation of the known tumor-causing effects of estrogens
could also be a toxic outcome. In all cases, the affected
organism or population would function differently, and
would likely be harmed.
Many tissues in both men and women have ERs.
Besides the pituitary and reproductive organs, many
other systems (eg. bone, brain, heart) could be nega-
tively affected by the interference of xenoestrogen
actions with physiologic estrogens. Functioning might
be changed directly at the level of the ER-containing tis-
sue, or via downstream activities (such as PRL released
from the pituitary and then acting on other tissues).
Many other tissues can be indirectly affected or need
coordinate regulation by estrogenic actions because they
are involved in supporting downstream reproductive
functions. For example, pregnancy puts stress on bones
due to weight gain, increases nutritional needs via the
gut and associated metabolic organs, increases cardio-
vascular load, requires changes in behaviors, and must
suspend some immune system responses to foreign
(fetal) antigens. There are several tissues related to such
changes upon which xenoestrogens have been reported
to have effects at low concentrations [3,4,8-10,78]. Male
reproductive and accessory glands also have ERs, and
xenoestrogens have been shown to affect the size and
function of these organs [79,80].
The levels of physiologic estrogens we have examined
here represent those at two very vulnerable life stages.
The low (10 pM) levels would be commensurate with
an infant or young undeveloped male or female long
before hormone levels rise at puberty. Certainly environ-
mental estrogens could have an impact at this stage,
when endogenous estrogens have not begun to rise to
the high levels required for reproductive tissue develop-
ment and function. The second level that we examined
(1 nM) typifies cycling females and early pregnancy, and
so would represent vulnerabilities to women during
their reproductive years. The levels of xenoestrogens we
studied represent those amounts expected to be present
i nt h em a j o r i t yo fA m e r i c a n sa c c o r d i n gt ot h ev a l u e s
reported by the NHANES database [34,81] for human
blood and urine, and are probably similar in inhabitants
of other developed countries. Exposures to xenoestro-
gens, especially at the low doses that we study (10 pM-
nM or 0.2-20 ppb), are therefore quite common as a
result of present-day environmental exposures. We see
evidence of non-monotonic dose-response behaviors
throughout our study results, a pattern that is now
recognized as typical of environmental and physiological
estrogen actions via the nongenomic pathways. The
hormesis effect [82] is somewhat evident here, where
the more potent are estrogenic effects, the greater is the
potential for inhibition of those effects at higher expo-
sure levels, in this case exacerbated by the combination
of estrogens. However, we can see these effects more
prominently in other studies where more detailed dose
responses were monitored [83]. Hormetic inhibitions are
very common in hormonal responses of many kinds,
and are thought by some to be safety mechanisms to
prevent overstimulation. It appears that for the purposes
of adding up the stimuli leading to signal integration at
the level of the MAPKs [1], both physiologic and non-
physiologic estrogens contribute to the final count, per-
haps pushing the total into the overstimulation range.
The mediators of these nongenomic responses are
mERs, so it is important to understand if their levels in
the membrane changed with these treatments. We had
previously observed such movements of mERs in and
out of the membrane in PC12 neuronal cells [13,14];
our findings there were consistent with the increased
presence of mERa i nt h em e m b r a n ea st h ep r i m a r y
mediator of estrogen-induced dopamine efflux from
these cells via the dopamine transporter. mERb and
GPER acted to mediate inhibition of this response, and
were consequently removed from the membrane under
the influence of a variety of estrogens that enhanced
dopamine effux. It is also possible that these receptors
do not actually leave the membrane, but may be shifted
to an inactive conformation that epitope-specific Abs to
ERs no longer recognize. However, that is not likely
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Page 10 of 13with the Abs we used, because such conformational
transformations affecting Ab recognition usually only
occur in the hinge region epitopes of ERs [84,85], and
here we used Abs recognizing the carboxy terminus.
The physiologic estrogens E1 and E3 also altered the
number of membrane ERbsa n dE R as, respectively, so
this may represent life stage-specific modulation of phy-
siologic functions by rapid movement of receptors in
and out of the membrane, a way for one endogenous
hormone to influence the actions of others. Because
alkylphenols and BPA dramatically downregulated
mERa and b in the membrane, especially at the higher
(nM) concentrations, it seems that this could be one of
the primary mechanisms of their actions. Even though
xenoestrogens did not affect GPER levels in the mem-
brane in our study, several have been shown to bind to
GPERs expressed by transfection in HEK293 cells [86].
Interestingly, E3 has recently been shown to be an
antagonist at GPER, though it does not alter the pre-
sence of GPER in the membrane [87].
Trafficking actions would not only affect the signaling
and functional responses to xenoestrogens at this rapid
time point, but also have consequences for the subse-
quent actions of physiologic estrogens via these recep-
tors. Where these receptors go, or when they return, is
not addressed by our studies, but others have suggested
that dynamic movement in and out of the membrane is
part of the necessary cycling that supports estrogenic
functions in a variety of tissues [88,89].
Conclusions
By designing medium-throughput, quantitative assays to
assess multiple nongenomic responses, we have been
able to compare the potencies and efficacies of several
structurally related xenoestrogens for important para-
meters of signaling, function, and receptor trafficking in
pituitary cells. In contrast to their weak actions via
genomic signaling pathways, these compounds are pro-
foundly effective in disrupting nongenomic responses to
multiple endogenous estrogens at concentrations that
represent different life stages. These mechanistic expla-
nations for the activities of xenoestrogens at low con-
centrations help explain their actions on the functions
of exposed animals and humans both during develop-
ment and in reproductive adulthood, and confirm our
concern about continuing to allow such xenoestrogens
to contaminate our environment.
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